TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02992509

Intervention type: DEVICE
Group type: OTHER
Intervention: EMED detruset(TM) intravesical electrical stimulation
Description: There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered.
Study: NCT00916019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 60 min of low-intensity exercise, 5 days/week, 12 weeks
Study: NCT00651274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
Study: NCT02189837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT00748319

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of KIR receptor by RT PCR
Description: Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
Study: NCT00005818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV
Study: NCT01183169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ALV placebo soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ALV placebo soft gel capsules administered orally
Study: NCT01514396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiseal
Description: surgical glue
Study: NCT01166828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TELLEPUPPS
Description: The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TELLEPUPPS
Description: The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
Study: NCT00005818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04077515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus(0.8mg/m2)
Description: The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus(0.7mg/m2)
Description: The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Study: NCT03042884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete.
Study: NCT00939211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Solution for inhalation through nebulization, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Dry powder for inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00972309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell receptor alternate reading frame protein (TARP) peptide vaccine
Description: Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Description: Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
Study: NCT01687985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 laxative - low dose
Description: BLI801 laxative - oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 laxative - high dose
Description: BLI801 laxative - oral solution
Study: NCT00216112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib mesylate 600 mg po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
Study: NCT03459092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin injection in the horizontal extraocular muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Description: Strabismus surgery on the horizontal extraocular muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strabismus surgery
Description: Strabismus surgery on the horizontal extraocular muscles
Study: NCT01028599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physical exercise
Description: Intensive physical exercise 1 hour three times per week
Study: NCT05277805

Intervention type: OTHER
Intervention: EMPOWER-UP questionnaire
Description: Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
Study: NCT01851031

Intervention type: PROCEDURE
Group type: OTHER
Intervention: the minor approach
Description: Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the minor approach
Description: Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
Study: NCT03016520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20164
Study: NCT04609436

Intervention type: DEVICE
Intervention: Cardiac monitoring with the wireless device SmartCardia
Description: Monitoring of arrhythmia with a wireless device (SmartCardia)
Study: NCT00859495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum-based antineoplastic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Folate Analog Metabolic Inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard procedure given 3 weeks after last dose of chemotherapy
Study: NCT00854776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: 30 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aluminum hydroxide 334 mg and Mg hydroxide 166 mg
Description: 1 tablet once daily
Study: NCT03688841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridged V.A.C.® with compression therapy
Description: Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Compression Therapy
Description: Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
Study: NCT01354964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00887822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV infusion on Day 1 of every 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bevacizumab on Day 1 of every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Study: NCT02592980

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic anticoagulation
Description: The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional anticoagulation
Description: The physician will adjust the dose according to current INR value based on guidelines.
Study: NCT02473029

Intervention type: RADIATION
Intervention: Vascular tomodensitometry

Intervention type: OTHER
Intervention: Magnetic resonance angiography

Intervention type: OTHER
Intervention: Vascular ultrasonography

Intervention type: OTHER
Intervention: Retinal angiography

Intervention type: OTHER
Intervention: Retinal optical coherence tomography
Study: NCT01219959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dianeal, Extraneal, Nutrineal
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
Study: NCT00262457

Intervention type: DEVICE
Group type: OTHER
Intervention: Implanted gluteal electrical stimulation system
Description: Implanted electrical stimulation system incorporating BION microstimulators
Study: NCT00676468

Intervention type: OTHER
Group type: OTHER
Intervention: Active Montelukast + Fish Oil Placebo
Description: Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Active Fish Oil + Montelukast Placebo
Description: 10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Active Montelukast + Active Fish Oil
Description: 1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
Study: NCT03204331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study: NCT00984958

Intervention type: DEVICE
Group type: OTHER
Intervention: Bulkamid
Description: injection of Bulkamid in the urethra

Intervention type: DEVICE
Group type: OTHER
Intervention: Bulkamid expectation
Description: expectance
Study: NCT05950399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo resting echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Echocardiography
Description: Undergo stress echocardiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Echocardiography
Description: Undergo stress echocardiography
Study: NCT02189837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered by mouth
Study: NCT03575741

Intervention type: DIAGNOSTIC_TEST
Intervention: Balance Tests
Description: Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes.
Study: NCT02189837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Atorvastatin
Description: Administered by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Atorvastatin
Description: Administered by mouth
Study: NCT01597778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Bone Marrow Transplant
Description: The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Umbilical Cord Blood Transplant
Description: The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35
Study: NCT02419781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rescue endovascular therapy
Description: endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No endovascular therapy
Study: NCT01624025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
Description: Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
Description: Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
Study: NCT02214992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril tablet
Study: NCT01088958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (Sprinkles)
Description: Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg
Study: NCT01434914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octenisept®
Description: Cutaneous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous use
Study: NCT05593744

Intervention type: OTHER
Intervention: no intervention
Description: This is an observational study so not involved intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observational study so not involved intervention
Study: NCT01439581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping System
Description: Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Mapping System
Description: Standard ICU bed with no mapping system